Elevance Health stock draws fresh institutional buying as consensus targets stay above current level
Elevance Health stock (ELV) is attracting new institutional buying in August 2026, even though its share price trades below consensus analyst targets and fair value estimates. Analysts maintain a "Moderate Buy" rating with price targets in the $440 range, indicating potential upside, and view the company as undervalued relative to its estimated fair value. The company's Carelon health services platform is highlighted as a key growth engine, driving both revenue and margin expansion.
Can Humana's Star Ratings Rebound Unlock MA Earnings Power?
Humana Inc. (HUM) is focusing on improving its Medicare Advantage (MA) Star Ratings to drive earnings growth and achieve a sustainable pretax margin of at least 3% by 2028. Early efforts show promising results in clinical quality and member engagement, with the upcoming October CMS Stars release being a crucial test. A successful rebound could significantly enhance MA plan economics and investor confidence, while peers like UnitedHealth Group (UNH) and Elevance Health (ELV) also prioritize MA quality.
CareCloud confirms massive data breach after 3.7M patients’ records stolen – What we know
CareCloud has confirmed a massive data breach that compromised the medical and personal records of over 3.7 million patients. The March cyberattack, which involved hackers accessing and removing data from CareCloud’s Amazon Web Services account, is now the fifth-largest US healthcare data theft of 2026. Stolen information includes names, addresses, Social Security numbers, medical records, government IDs, and financial details, leaving affected individuals vulnerable to identity theft and fraud.
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability
Amid rising bankruptcy filings and recession warnings, this article identifies three dividend-focused healthcare stocks for investors seeking stability: Abbott Laboratories (ABT), Elevance Health (ELV), and UnitedHealth Group (UNH). These companies offer defensive traits, recurring revenues, and established dividend records, making them potential candidates for portfolios looking for steadier ground in a volatile market. The article details each company's business model, revenue streams, and factors influencing their dividend profiles and financial stability.
UnitedHealth Stock Looks Reasonable at 18.39X P/E: Should You Buy Now?
UnitedHealth (UNH) is trading at 18.39X forward 12-month earnings, below its five-year median P/E, suggesting a modest discount despite being above the industry average. The company has shown improved medical care ratios and upward earnings estimate revisions, with analysts seeing further upside. However, regulatory scrutiny, potential tax issues, and membership declines pose ongoing risks.
Elevance Health stock trades around $400 as Q2 2026 earnings beat supports upbeat outlook
Elevance Health stock is trading around $400, supported by a strong Q2 2026 earnings beat with adjusted EPS of $7.45 against a $6.21 consensus. The company reported modest revenue growth, but profit expansion outpaced top-line growth, leading to an upbeat full-year EPS forecast of $27.07 for 2026. Analysts maintain a "Buy to Moderate Buy" rating with an average price target of $440.90, indicating potential upside despite a slight membership decline.
UnitedHealth Stock Looks Reasonable at 18.39X P/E: Should You Buy Now?
UnitedHealth (UNH) stock is trading at 18.39X forward 12-month earnings, below its five-year median but above the industry average, suggesting a premium for its strong market position. The company has seen improved medical costs, upward earnings estimate revisions for 2026 and 2027, and significant capital returns to shareholders. Despite ongoing regulatory scrutiny and potential membership declines, the stock carries a Zacks Rank #2 (Buy) due to its favorable risk-reward profile and solid fundamentals.
ELV|Elevance Health Inc|Price:399.980|Chg%:+9.740
This article provides a comprehensive stock analysis of Elevance Health Inc (ELV) from TradingKey, highlighting its stable fundamentals and significant growth potential. The company is considered fairly valued within the Healthcare Providers & Services industry and has received multiple "Buy" ratings from analysts. Despite average market performance recently, the stock is suitable for range-bound swing trading due to its sideways movement between support and resistance levels.
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks
This article analyzes the Q2 performance of healthcare providers and services stocks, highlighting top performers like McKesson and CVS Health, and the weakest, AdaptHealth. It discusses the sector's general trends, including consistent demand versus high operational costs and regulatory pressures, while also touching upon broader market risks like AI and geopolitics.
Soon you can buy Medicare Advantage plans at Costco. What you need to know.
Costco Wholesale is expanding its offerings by partnering with nonprofit insurer SCAN Group to sell jointly branded Medicare Advantage and Medicare supplement plans. This move makes Costco the latest consumer brand to venture into offering health insurance options. The new plans will be available alongside Costco's existing wide range of products and services.
Elevance Health Inc. stock outperforms competitors on strong trading day
Elevance Health Inc. (ELV) saw its stock rise by 2.06% to $398.27 on Tuesday, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The company's stock closed 8.70% below its 52-week high, indicating a strong performance relative to the broader market on that particular trading day. This suggests resilience for Elevance Health Inc. in a challenging economic environment.
How Should You Approach CVS Health Stock After Q2 Earnings?
CVS Health reported strong Q2 2026 results with significant revenue and adjusted operating income growth across all segments, leading management to raise its full-year outlook for adjusted EPS and cash flow. Despite the strong performance and outperformance against benchmarks and peers over the last 12 months, the stock saw a 5.1% dip after earnings. The company faces near-term challenges with its Caremark 340B business and potential membership declines but maintains an attractive valuation, suggesting existing shareholders might hold, while new investors may seek a better entry point.
Elevance Health Inc. stock underperforms Monday when compared to competitors
Elevance Health Inc.'s stock (ELV) fell by 2.52% on Monday, closing at $390.24, underperforming the broader market. This occurred during a grim trading session where the S&P 500 Index and Dow Jones Industrial Average also declined. The stock is currently 10.54% below its 52-week high of $436.24, reached on July 14th.
Health systems test real-time prior auths through Epic
Four health systems—Ochsner Health, Froedtert ThedaCare, Denver Health, and Summit Health—are piloting Epic's new Coverage Requirements Discovery (CRD) API to streamline prior authorizations for major insurers. This API integrates prior authorization requirements directly into the EHR system at the point of scheduling or order placement, aiming to reduce administrative burden and comply with upcoming federal interoperability rules. The initiative seeks to make real-time prior authorizations possible, addressing a long-standing pain point for providers and improving patient care efficiency.
Why is Centene stock sliding today?
Centene Corp (CNC) stock dropped over 3% in morning trading after the announcement of CFO Drew Asher's planned departure and succession by Chris Neczypor. The leadership change comes at a sensitive time for Centene, which is undergoing a financial turnaround, causing investors to focus on potential continuity risks despite reaffirmed EPS guidance. The stock's recent rally to near its 52-week high also contributed to investor reassessment, with the broader market offering no buffer.
U.S. Mental Health Treatment Market Report 2026–2030: Evaluating $159 Billion Forecast, Digital App Adoption, and Strategies of Acadia Healthcare, UHS, Talkspace, and Elevance Health
A new report by Marketdata LLC examines the U.S. mental health services market, forecasting its value to reach $159 billion by 2030. The study analyzes the impact of clinical facility expansion, payer integration, and the growth of digital therapy platforms from companies like Acadia Healthcare, UHS, Talkspace, and Elevance Health. It also addresses the industry's fragmentation, sustained demand, technology adoption, and ongoing challenges related to workforce shortages and accessibility.
PRVA|Privia Health Group Inc|Price:22.000|Chg%:+0.240
This article provides a detailed overview of Privia Health Group Inc (PRVA) stock, including its current price, market data, key figures, and financial performance metrics. It also features a "TradingKey Stock Score," analyst ratings with a target price, and a company profile outlining its business model and shareholder information. The stock currently has an overall "Buy" rating from analysts with a significant upside potential.
State of Wyoming Takes $1.76 Million Position in Elevance Health, Inc. $ELV
The State of Wyoming acquired a new $1.76 million stake in Elevance Health (NYSE:ELV) during the second quarter, purchasing 4,564 shares. This move comes as Elevance Health reported strong quarterly earnings, beating analyst expectations with an EPS of $7.45 and revenue of $49.83 billion. The company also declared a quarterly dividend of $1.72 per share, and analysts maintain a "Moderate Buy" rating with an average price target of $440.90.
Stoneridge Investment Partners LLC Acquires New Shares in Elevance Health, Inc. $ELV
Stoneridge Investment Partners LLC has acquired 2,581 new shares of Elevance Health, Inc. (NYSE:ELV) during the second quarter, valuing approximately $970,000. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 89.24% of the company's stock. Analysts maintain a "Moderate Buy" rating with an average price target of $440.90 for Elevance Health, following strong quarterly earnings that exceeded expectations with $7.45 EPS and $49.83 billion in revenue.
GSA Capital Partners LLP Buys New Holdings in Elevance Health, Inc. $ELV
GSA Capital Partners LLP has acquired a new stake of 9,037 shares in Elevance Health, Inc. valued at approximately $3.495 million during the second quarter. This move is part of broader institutional interest, with several other funds also adjusting their positions in ELV. Elevance Health recently reported strong Q2 earnings, exceeding analyst expectations, and announced a quarterly dividend of $1.72 per share.
Family Legacy Inc. Buys New Stake in Elevance Health, Inc. $ELV
Family Legacy Inc. acquired a new stake in Elevance Health, Inc. (NYSE:ELV) during the second quarter, purchasing 7,435 shares valued at approximately $2.875 million. Other institutional investors also increased their holdings, with hedge funds and institutions now owning 89.24% of the stock. Elevance Health reported strong quarterly earnings, beating estimates with an EPS of $7.45 and revenue of $49.83 billion, and also declared a quarterly dividend of $1.72 per share.
Empowered Funds LLC Has $6.70 Million Stock Holdings in Elevance Health, Inc. $ELV
Empowered Funds LLC significantly reduced its stake in Elevance Health (NYSE:ELV) by 75.1% in the first quarter, selling over 69,000 shares but still retaining holdings worth approximately $6.70 million. Despite this reduction, institutional investors collectively own a substantial 89.24% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for Elevance Health, with a consensus price target of $440.90, following strong quarterly earnings that exceeded expectations.
Humana Stock Gains 1.1% as 600,000-Member Medicare Reset Tests Its 2028 Margin Plan
Humana (NYSE:HUM) shares rose 1.1% last week as the company navigates a significant Medicare Advantage reset, planning to exit approximately 600,000 members while aiming to retain 40% in other offerings. This strategy is designed to achieve a sustainable pre-tax margin of at least 3% by 2028. Despite rising medical costs, Humana reported strong Q2 2026 results with revenue up 26.2% and adjusted EPS up 21.4%, and continues to forecast at least $9.00 adjusted EPS for the full year.
Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue?
Elevance Health (ELV) has seen its shares rise 6.8% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates due to higher CarelonRx product revenues, despite a decline in medical membership and an elevated expense level. Investors are now questioning whether this positive trend will continue leading up to its next earnings release.
Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue?
Elevance Health (ELV) has seen its shares rise 6.8% since its last earnings report, outperforming the S&P 500. The company reported better-than-expected Q2 2026 adjusted EPS, driven by higher premium yields and CarelonRx product revenues, despite a decline in medical membership and elevated expenses. Elevance Health has also revised its 2026 adjusted EPS outlook upwards, though estimates have shown a downward trend recently, resulting in a Zacks Rank #3 (Hold).
Can Humana Improve Caregiver Retention With HealthStream Deal?
Humana's Medicaid plan, Humana Healthy Horizons, is partnering with HealthStream in Indiana to enhance the home-care workforce by offering 1,000 Home Health Aide scholarships and deploying advanced training tools. This initiative aims to combat high caregiver turnover, with early results showing improved retention for participating providers. Other healthcare peers like UnitedHealth Group and Elevance Health are also implementing strategies to address the home-care workforce shortage.
Western Wealth Management LLC Increases Stock Position in Elevance Health, Inc. $ELV
Western Wealth Management LLC significantly increased its stake in Elevance Health (NYSE:ELV) by 205.9% in Q1, holding 3,738 shares valued at $1.09 million. This move comes as institutional investors collectively own 89.24% of the company, and analysts maintain a "Moderate Buy" rating despite recent price target reductions. Elevance Health reported strong quarterly earnings, beating EPS estimates by $1.24 and declaring a dividend of $1.72 per share.
Can UNH's Lower Medical Costs Sustain the Earnings Recovery?
UnitedHealth Group (UNH) has shown an improved earnings performance in Q2, with a lower medical care ratio (MCR) of 86.7%, driven by reduced medical costs in Medicare and OptumHealth's focus on value-based care. While this trend is encouraging and has led UNH to raise its 2026 EPS guidance, rising commercial medical costs and the durability of these cost controls remain key factors for sustained earnings growth. Peers like Elevance Health (ELV) and CVS Health (CVS) are also navigating similar cost trends, with varying degrees of success and challenges.
Medicare Will Spend More Than $13 Billion on the Medicare Advantage Quality Bonus Program in 2026
Medicare's spending on the Medicare Advantage quality bonus program is projected to reach over $13 billion in 2026, a substantial increase from previous years. While most Medicare Advantage enrollees are in plans qualifying for bonuses, the share has recently declined. The program's costs and benefits, particularly for different plan types and insurers, are subject to ongoing debate and analysis, with recent CMS recalculations further impacting spending.
Handelsbanken Fonder AB Has $30.86 Million Position in Elevance Health, Inc. $ELV
Handelsbanken Fonder AB increased its stake in Elevance Health, Inc. ($ELV) by 7.8% during the second quarter, bringing its total holdings to 79,811 shares valued at approximately $30.86 million. Elevance Health reported strong quarterly earnings, beating analyst expectations with an EPS of $7.45 and revenue of $49.83 billion. Analysts have a "Moderate Buy" consensus rating for ELV with an average price target of $440.90, and the company also declared a quarterly dividend of $1.72 per share.
NewEdge Advisors LLC Has $5.55 Million Holdings in Elevance Health, Inc. $ELV
NewEdge Advisors LLC increased its stake in Elevance Health, Inc. (NYSE:ELV) by 21.4% in the first quarter, bringing its total holdings to 18,964 shares valued at $5.55 million. Other institutional investors also adjusted their positions in the company. Elevance Health has a "Moderate Buy" consensus rating from analysts, with a target price of $440.90, and recently reported strong quarterly earnings and declared a dividend.
Elevance Health Inc. stock underperforms Tuesday when compared to competitors
Elevance Health Inc. (ELV) stock fell 1.84% to $390.37 on Tuesday, underperforming the broader market. This drop occurred during a negative trading session where both the S&P 500 and Dow Jones Industrial Average also declined. The stock's fall ended a four-day winning streak.
$14.75 Million, 4 Million Documents, One Opt-Out: Nurses’ Overtime Fight With Elevance Health Nears Its End
Nurses who accused Elevance Health of misclassifying them as exempt from overtime pay have sought final court approval for a $14.75 million settlement. The settlement covers 524 class members across four states, with only one opting out and none objecting, signaling strong class approval. The case highlighted differing judicial interpretations of the "learned professional" exemption, ultimately pushing both sides to a negotiated resolution.
b.well Connected Health Named in the Inaugural Gartner® Magic Quadrant™ for Healthcare Provider Industry Cloud Platforms
b.well Connected Health has been recognized as a Niche Player in Gartner's inaugural Magic Quadrant for Healthcare Provider Industry Cloud Platforms. The company's platform, built on a FHIR-native data foundation, focuses on creating personalized, shoppable consumer health experiences by unifying fragmented health data. This inclusion highlights b.well's role in the industry's shift towards cloud platforms that integrate data, intelligence, and digital experiences, supporting national interoperability initiatives like the CMS Health Tech Ecosystem.
Cigna targets mid-market employers with Northern California appointment
Cigna Healthcare has appointed Luke Cirkovic as general manager for its Northern California market, focusing on employers with up to 2,999 employees. This move aligns with Cigna's strategic shift to prioritize its US employer business, following the sale of its Medicare Advantage business and exit from individual and family plans. Cirkovic, a stop-loss and multi-line specialist, brings over 20 years of experience, signaling Cigna's intensified push into a segment that generates significant broker activity amid a tightening stop-loss market.
Humana Names James P. Holland President of Medicaid
Humana Inc. (NYSE: HUM) has appointed James "J.P." Holland as Senior Vice President and President of Medicaid, effective August 17. Holland will lead Humana's Medicaid business, which serves over 1.6 million members across 11 states, reporting to Aaron Martin, President of Insurance. He brings extensive experience from previous leadership roles at Johns Hopkins Health Plans, Elevance Health, Amerigroup, and WellCare Health Plans.
Anthem, Inc. Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach involving WellPoint Texas, Inc., a Texas Medicaid managed care company. The breach, reported to the Texas Attorney General on August 10, 2026, affected 101,047 individuals, potentially exposing names, addresses, health insurance information, and dates of birth. Individuals affected by the breach may be entitled to compensation and are encouraged to join a class-action lawsuit to protect their rights.
Elevance Health, Inc. $ELV Shares Sold by Maj Invest Holding A S
Maj Invest Holding A S reduced its stake in Elevance Health (NYSE:ELV) by 11.6% in the second quarter, selling 30,183 shares but still holding 229,987 shares valued at $88.9 million. Institutional investors collectively own 89.24% of the company. Elevance Health has a "Moderate Buy" consensus rating from analysts, with an average price target of $440.90, and recently reported strong quarterly earnings and declared a dividend of $1.72 per share.
Professional Advisory Services Inc. Sells 8,231 Shares of Elevance Health, Inc. $ELV
Professional Advisory Services Inc. reduced its stake in Elevance Health, Inc. by 10.7% in the second quarter, selling 8,231 shares but still holding 68,657 shares valued at $26.6 million. Despite this sale, institutional ownership remains high at 89.24%, with several major investors increasing their positions. Analysts generally maintain a "Moderate Buy" rating for Elevance Health, setting an average price target of $440.90, especially after the company surpassed its quarterly earnings expectations and declared a $1.72-per-share dividend.
PensionDanmark Pensionsforsikringsaktieselskab Trims Stock Holdings in Elevance Health, Inc. $ELV
PensionDanmark Pensionsforsikringsaktieselskab reduced its stake in Elevance Health, Inc. by 21.1% in the second quarter, selling over 15,000 shares but still retaining a significant holding valued at approximately $22.2 million. Despite this trim, institutional investors collectively own 89.24% of the stock. Elevance Health reported strong Q2 earnings, beating EPS and revenue expectations, and declared a quarterly dividend of $1.72 per share, while analysts maintain a "Moderate Buy" rating with an average price target of $440.90.
Assenagon Asset Management S.A. Buys 184,595 Shares of Elevance Health, Inc. $ELV
Assenagon Asset Management S.A. significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 160.8% in the second quarter, acquiring an additional 184,595 shares. Other institutional investors also adjusted their holdings in ELV, with notable increases from Wellington Management Group LLP and Price T Rowe Associates Inc. MD. Elevance Health recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $1.72 per share.
Nutex Health, Inc. Q2 2026 Earnings Call Summary
Nutex Health, Inc. reported a significant 3,100% year-over-year increase in net income for Q2 2026, driven by reduced earn-out and arbitration costs, despite a slight revenue decrease attributed to timing differences. The company saw 6.3% same-hospital visit growth and reinforced its strategy to leverage Independent Dispute Resolution (IDR) for fair reimbursement while expanding clinical capabilities and maintaining a strong liquidity position. Management also detailed structural adjustments, including a new "pay-on-collected" model for the HaloMD contract and reduced CMS IDR fees, which are expected to lower future arbitration expenses.
Axogen (AXGN) Q2 2026 Earnings Call Transcript
Axogen (AXGN) reported strong Q2 2026 financial results with revenue up 23.1% year-over-year, driven primarily by significant growth in its Breast segment. The company raised its full-year revenue guidance to at least $279 million, reflecting confidence in its commercial execution and sales force productivity, though it revised its gross margin guidance to at least 73% due to a shift in product mix towards higher-cost breast procedures. Axogen also highlighted strategic investments in imaging technology and ongoing clinical development in prostate repair, emphasizing its commitment to expanding peripheral nerve care.
Centene Corp (CNC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Centene Corp (CNC) has an earnings forecast score of 6.87, ranking 48th in the Healthcare Providers & Services industry, with an average price target of $40.00. Analysts' ratings show a majority "Hold" signal based on 23 analysts. The company's expected revenue for the next quarter is $47.11 billion, and the previous quarter's EPS was $3.13 against an expectation of $2.21, with the next quarter's EPS projected at $0.10.
Graves Light Lenhart Wealth Inc. Acquires 3,603 Shares of Elevance Health, Inc. $ELV
Graves Light Lenhart Wealth Inc. significantly increased its stake in Elevance Health (NYSE:ELV) by 124.2% in Q2, adding 3,603 shares to reach a total of 6,505 shares valued at $2.52 million. Wall Street analysts maintain a "Moderate Buy" consensus for ELV, with an average price target of $440.90. Elevance Health recently surpassed earnings expectations with $7.45 per share and reported $49.83 billion in revenue, also declaring a quarterly dividend of $1.72 per share.
Diamond Hill Capital's Top Q2 2026 Move: Trimming Texas Instruments Inc at a -1.5% Portfolio Impact
Diamond Hill Capital's Q2 2026 13F filing reveals a strategic rebalancing, with significant reductions in certain large-cap holdings like Texas Instruments Inc, impacting the portfolio by -1.5%. The firm also initiated 12 new positions in sectors such as healthcare and energy, with Elevance Health Inc being the largest new addition. These moves reflect a deliberate reallocation of capital guided by their disciplined bottom-up research approach.
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections
Pediatrix Medical Group (MD) reported strong second-quarter 2026 earnings, surpassing analyst estimates due to improved cash collections, a favorable payor mix, and recent acquisitions. Despite higher operating costs and lower patient volumes, the company saw an 18.9% increase in adjusted EPS and a 4.1% rise in net revenues. MD reaffirmed its 2026 guidance for adjusted EBITDA, projecting it to be between $280 million and $300 million.
Pediatrix Medical Tops Q2 Earnings on Better Cash Collections
Pediatrix Medical Group (MD) reported strong second-quarter 2026 results, surpassing earnings and revenue estimates due to improved cash collections and a favorable payor mix, despite facing lower patient volumes and higher operating costs. The company's adjusted EPS increased by 18.9% year over year, and net revenues grew by 4.1%. Management reaffirmed its adjusted EBITDA guidance for 2026 and provided updated estimates for net income and various expenses.
FXH Dividend: 0.66% Yield, $1.03/Share — History & Dates
This article provides a detailed dividend history and financial metrics for the First Trust Health Care AlphaDEX Fund (FXH). It highlights FXH's current dividend yield of 0.66%, an annual payout of $1.03 per share, and a 5-year dividend growth rate of 15.27%. The fund has been paying dividends since 2010, and the piece includes a comprehensive table of past dividend payments and ex-dividend dates.
Inuvo’s IntentKey a Powerful Tool in Identifying Net-New Open Enrollment Customers
Inuvo announced that its IntentKey AI advertising technology successfully helped a leading health plan identify and target net-new consumers, significantly improving year-over-year enrollment during the recent open enrollment period. The pilot validated IntentKey's ability to drive ROI by recognizing emerging demand before it becomes explicit, providing insights into consumer motivations, and enabling real-time targeting without relying on personal identities. This innovative approach offers health plans a competitive advantage in a highly saturated market by focusing on real-time content engagement and predictive intelligence.
